Sector Update: Health Care Stocks Increase Late Afternoon
Health care stocks were advancing late Monday afternoon with the NYSE Health Care Index adding 0.6% and the Health Care Select Sector SPDR Fund (XLV) up 0.5%. The iShares Biotechnology ETF (IBB) climb
Sector Update: Health Care
Health care stocks increased late Monday afternoon with the NYSE Health Care Index adding 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) climbed 1.
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
Friday, Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) said it has begun winding down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as announced in December 2023.A
Top Midday Decliners
Hepion Pharmaceuticals (HEPA) plummeted 30% Monday, after disclosing the wind-down activities in its phase 2b trial of rencofilstat, while continuing to explore strategic alternatives. "We are disappo
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock.
MRIN, WISA and SMFL Among Mid-day Movers
SBFM, BPTH and INDO Among Pre-market Losers
Express News | Hepion Pharmaceuticals Shares Are Trading Lower After the Company Announced That It Began Wind-down Activities in Its Phase 2b "ASCEND-NASH Trial
Stocks to Watch: Hepion Pharma, Tungray Technologies, Tesla
By Dean Seal Hepion Pharmaceuticals said after the bell that it has started winding down activities in its Ascend-Nash trial of the drug candidate rencofilstat, which had been shown to reduce liver f
Hepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trial
By Stephen Nakrosis Shares of Hepion Pharmaceuticals dropped in post-market on Friday after it disclosed plans to wind down its Ascend-Nash trial, which was evaluating the safety and efficacy of renc
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Express News | Hepion Pharmaceuticals Shares Resumed Trading
Express News | Trading Halt: Halt Status Updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times
Express News | Hepion Pharmaceuticals Inc - There Were No Safety Concerns Observed for Rencofilstat in Ascend-Nash Trial
Express News | Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2B ‘Ascend-Nash’ Trial
Express News | Trading Halt: Halted at 4:25:20 P.m. ET - Trading Halt: Halt News Pending
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
The NASH pharmaceutical market is expected to exceed $48 billion by 2035, and companies such as Novo Nordisk (NVO.US) and Lily.US (LLY.US) will begin to deploy
According to international consulting firm Research Nester, the global non-alcoholic steatohepatitis (NASH) treatment market is expected to reach US$48.3 billion by 2035.
NASH Drug Market Expected to Surpass $48B by 2035
No Data